Harvard Bioscience, Inc. has entered into a definitive merger agreement to acquire 100% of the outstanding stock of Data Sciences International, Inc. for approximately $70 million (subject to adjustment for net working capital and other customary adjustments). As a result of these transactions, management expects the company's fiscal 2018 annual revenue to be between $118 million and $123 million. The Company expects gross profit margins under generally accepted accounting principles to be between 54% and 57%, GAAP operating margins to be between 4% and 7%, and GAAP earnings per share to be between $0.03 and $0.07.

These estimates equate to non-GAAP adjusted gross profit margins of between 54% and 57%, non-GAAP adjusted operating margins of between 10% and 13%, and non-GAAP adjusted EPS of between $0.19 and $0.23, respectively.